Mirabegron, vibegron equally effective in postmenopausal women with OAB
Mirabegron appears to be as good as vibegron in the treatment of overactive bladder (OAB) in postmenopausal women, with both drugs helping improve symptoms and the parameters of voiding diary, according to a study.
A total of 199 women with treatment-naïve OAB were randomly assigned to receive mirabegron 50 mg (n=97) or vibegron 50 mg (n=102) daily for 12 weeks. Researchers evaluated the OAB symptom score (OABSS) and quality of life (QOL) index at baseline and at 4 and 12 weeks. The patients’ 3-day voiding diary and postvoided residual urine volumes were evaluated at baseline and 12 weeks.
The outcomes of OABSS, QOL index, the numbers of micturition, urgency episodes, incontinence episodes, and voided volume per 24 hours all improved from baseline to week 12 in both treatment groups. The rate of change in the two groups was not significantly different.
Likewise, the postvoid residual urine volume was similar in the mirabegron and vibegron in the two groups at 12 weeks.
Adverse effects led to treatment discontinuation in 6.2 percent of patients in the mirabegron group and in 6.8 percent in the vibegron group, with no significant between-group difference.
The findings suggest that both mirabegron and vibegron are useful for treating OAB symptoms in postmenopausal women.